We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Soterius Selects MIP Diagnostics’ Synthetic Antibodies for Instant COVID-19 Biosensor
Product News

Soterius Selects MIP Diagnostics’ Synthetic Antibodies for Instant COVID-19 Biosensor

Soterius Selects MIP Diagnostics’ Synthetic Antibodies for Instant COVID-19 Biosensor
Product News

Soterius Selects MIP Diagnostics’ Synthetic Antibodies for Instant COVID-19 Biosensor

Credit: PIRO4D/ pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Soterius Selects MIP Diagnostics’ Synthetic Antibodies for Instant COVID-19 Biosensor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Soterius, an Australian medical device startup in the field of respiratory infection has selected MIP Diagnostics, a UK specialist in molecularly imprinted polymers for the affinity reagent in their novel COVID-19 biosensor.

The Soterius biosensor utilizes MIP Diagnostics’ COVID-19 nanoMIP, which acts as a synthetic antibody to the SARS-CoV-2 spike protein. The sensor registers a change in resistance in the presence of the COVID-19 virus and gives results in as little as 2 minutes. The device will enable regular, rapid detection of COVID-19 virus in hospitals, clinics, and other high traffic sites. Currently in development, initial results have proven extremely promising, with sensitivity in the picogram scale.

Alasdair Wood, CTO at Soterius said, “We are always looking for new technologies that can support the development of smart biosensors. The robust characteristics of nanoMIPs make them ideal for our manufacturing processes without compromising on sensitivity. We look forward to working with MIP Diagnostics as we expand our portfolio of respiratory diagnostic and management solutions.” Stephane Argivier, CEO at MIP Diagnostics added, “We are extremely excited to work with Soterius in contributing to a solution that will drive improvements in how we manage the COVID-19 pandemic. The pairing of our technologies will undoubtedly pave the way to improved sensing capabilities and diagnostics in the respiratory infection space. It’s great to work with technologies and partners such as Soterius to bring about a big impact to the future of how we manage the current and future pandemics.” 

Advertisement